BRIGHT is a generic drug manufacturer focused on Neurology, Oncology.
BRIGHT's Key Drugs
BRIGHT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
BRIGHT's Recent FDA Approvals
New NDA/BLA approvals for BRIGHT over the last two years — novel drugs only, excluding generics and label supplements.
BRIGHT's Therapeutic Areas
BRIGHT's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BRIGHT's Top Competitors
BRIGHT's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BRIGHT Pipeline Snapshot
BRIGHT has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-09-01
- Latest
- 2023-09-01
- Applications
- 1